Insider Selling: Keryx Biopharmaceuticals (KERX) CFO Sells 5,651 Shares of Stock

Keryx Biopharmaceuticals (NASDAQ:KERX) CFO Scott A. Holmes sold 5,651 shares of Keryx Biopharmaceuticals stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $4.81, for a total transaction of $27,181.31. The sale was disclosed in a filing with the SEC, which is available through this link.

Scott A. Holmes also recently made the following trade(s):

  • On Monday, January 29th, Scott A. Holmes sold 2,830 shares of Keryx Biopharmaceuticals stock. The shares were sold at an average price of $4.81, for a total transaction of $13,612.30.

Keryx Biopharmaceuticals (NASDAQ:KERX) opened at $4.89 on Monday. Keryx Biopharmaceuticals has a 1-year low of $4.01 and a 1-year high of $8.38. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.08). Keryx Biopharmaceuticals had a negative net margin of 269.52% and a negative return on equity of 2,494.37%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $17.53 million. During the same period in the prior year, the business earned ($0.32) earnings per share. The company’s revenue for the quarter was up 96.8% on a year-over-year basis. equities analysts forecast that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.

KERX has been the subject of several analyst reports. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Stifel Nicolaus cut their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, November 8th. Finally, Morgan Stanley cut their price target on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $7.19.

A number of institutional investors and hedge funds have recently bought and sold shares of KERX. Abrams Capital Management L.P. increased its position in Keryx Biopharmaceuticals by 69.9% in the 4th quarter. Abrams Capital Management L.P. now owns 9,719,176 shares of the biopharmaceutical company’s stock valued at $45,194,000 after acquiring an additional 4,000,000 shares in the last quarter. Clearbridge LLC increased its position in Keryx Biopharmaceuticals by 67.7% in the 4th quarter. Clearbridge LLC now owns 2,692,744 shares of the biopharmaceutical company’s stock valued at $12,521,000 after acquiring an additional 1,087,120 shares in the last quarter. Russell Investments Group Ltd. increased its position in Keryx Biopharmaceuticals by 742.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock valued at $5,358,000 after acquiring an additional 665,069 shares in the last quarter. Vanguard Group Inc. increased its position in Keryx Biopharmaceuticals by 5.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after acquiring an additional 349,521 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in Keryx Biopharmaceuticals by 19.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 1,911,657 shares of the biopharmaceutical company’s stock valued at $8,889,000 after acquiring an additional 310,485 shares in the last quarter. Hedge funds and other institutional investors own 67.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thelincolnianonline.com/2018/02/19/insider-selling-keryx-biopharmaceuticals-kerx-cfo-sells-5651-shares-of-stock.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply